Osteoporosis silently weakens bone, often with no symptoms until a fracture occurs — which is why screening before a fracture matters. It is both detectable (with a DXA bone-density scan) and treatable, and prevention can begin at any age through calcium and vitamin D, weight-bearing and resistance exercise, and fall prevention. Medicines can substantially reduce fracture risk, but which drug to use, how to dose and sequence it, and when to stop are decisions your clinician makes and monitors — this article gives no dosing and is general educational information, not medical advice. Sudden, severe back pain can signal a spinal fracture and should be evaluated promptly.
Roughly 10 million Americans have osteoporosis and tens of millions more have low bone density that places them at increased risk. Each year, osteoporosis contributes to more than 2 million fractures in the United States — a hip fracture, a crushed vertebra, a broken wrist — many of which lead to chronic pain, disability, and loss of independence. Osteoporosis is often called a “silent disease” because bone loss occurs without symptoms until a fracture happens. By that point, significant skeletal deterioration has usually already occurred. The good news: this condition is both detectable and treatable, and prevention strategies can begin at any age. For a broader view of chronic health conditions, visit our medical conditions guide. This guide is educational and is not a substitute for care from a qualified clinician.
What Is Osteoporosis?
Osteoporosis literally means “porous bone.” It is a skeletal disorder characterized by decreased bone mass and deterioration of the microscopic architecture of bone tissue, leading to increased fragility and susceptibility to fracture. According to the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), healthy bone is constantly being remodeled — old bone is broken down (resorption) by cells called osteoclasts, and new bone is formed by osteoblasts. In osteoporosis, resorption outpaces formation, resulting in net bone loss over time.
Bone density peaks in the late 20s to early 30s. After that, bone mass gradually declines. In women, the rate of bone loss accelerates sharply in the first 5 to 7 years after menopause because of the drop in estrogen. Men lose bone more gradually but are not immune — roughly 20 percent of people affected by osteoporosis are men, and the disease is underdiagnosed in them.
Osteoporosis is diagnosed using dual-energy X-ray absorptiometry (a DXA scan, sometimes written DEXA), which measures bone mineral density (BMD) and expresses it as a T-score. A T-score of -1.0 or above is normal. A T-score between -1.0 and -2.5 indicates osteopenia (low bone mass). A T-score of -2.5 or below indicates osteoporosis. The World Health Organization established these diagnostic thresholds, and they remain the standard worldwide. A diagnosis can also be made clinically after a fragility fracture (a fracture from a fall from standing height or less), regardless of the T-score.
Causes and Risk Factors
Osteoporosis can be primary (related to aging and hormonal changes) or secondary (caused by other medical conditions or medications). Primary osteoporosis includes postmenopausal osteoporosis, driven largely by estrogen deficiency, and age-related osteoporosis, which affects both men and women as hormonal and age-related factors converge.
Non-modifiable risk factors include female sex, older age, small body frame, a family history of osteoporosis or hip fracture, and certain ancestries associated with lower peak bone mass. According to the Mayo Clinic, women are considerably more likely than men to develop osteoporosis, owing to lower peak bone mass and the accelerated bone loss around menopause.
Modifiable risk factors include inadequate calcium and vitamin D intake, a sedentary lifestyle, cigarette smoking, excessive alcohol consumption, and low body weight. Secondary causes include long-term corticosteroid (glucocorticoid) use — the most common medication-related cause — hyperthyroidism, hyperparathyroidism, celiac disease, inflammatory bowel disease, rheumatoid arthritis, chronic kidney disease, type 1 diabetes, premature menopause, hypogonadism, and eating disorders such as anorexia nervosa.
Certain medications beyond corticosteroids can also accelerate bone loss: aromatase inhibitors used in breast-cancer treatment, proton pump inhibitors (with long-term use), some anti-seizure medications, medroxyprogesterone acetate (Depo-Provera), and androgen-deprivation therapy for prostate cancer. If you take any of these long-term, ask your prescriber whether your bone health should be monitored.
Symptoms and Fracture Risk
Osteoporosis itself produces no symptoms until a fracture occurs — which is exactly why screening is essential. The most common osteoporotic fractures affect the spine (vertebral compression fractures), hip, and wrist. According to the Bone Health & Osteoporosis Foundation (formerly the National Osteoporosis Foundation), a woman’s lifetime risk of an osteoporotic fracture is roughly 50 percent — a striking figure that underscores how common these injuries are.
Vertebral compression fractures are the most common osteoporotic fracture and often occur without a clear traumatic event — simply bending, lifting, or even coughing can cause a weakened vertebra to collapse. Many vertebral fractures are initially silent, but they can cause progressive height loss, kyphosis (a forward curvature of the upper spine, sometimes called a “dowager’s hump”), and chronic back pain.
Hip fractures are the most devastating consequence of osteoporosis. Roughly 300,000 hip fractures occur annually in the United States, and the outcomes are sobering: a substantial share of hip-fracture patients die within one year, and many never regain their pre-fracture level of function. Wrist fractures (distal radius fractures), often caused by falling onto an outstretched hand, tend to occur earlier — frequently in the 50s and 60s — and can serve as an early warning sign of declining bone strength.
A sudden episode of severe back pain, especially after a minor movement such as bending, lifting, or coughing, and especially in an older adult or someone with known low bone density, can signal a vertebral compression fracture and should be evaluated promptly by a clinician. Seek emergency care if back pain is accompanied by new leg weakness or numbness, difficulty walking, or any loss of bladder or bowel control, which can indicate nerve or spinal-cord involvement and needs immediate attention.
Screening and Diagnosis
In its January 2025 recommendation, the U.S. Preventive Services Task Force (USPSTF) advises bone-density screening with a DXA scan for all women aged 65 and older (a Grade B recommendation), and for postmenopausal women younger than 65 who have one or more risk factors for osteoporosis — such as low body weight, a parent’s history of hip fracture, smoking, or excess alcohol use — typically identified first with a clinical risk-assessment tool (also Grade B). For men, the USPSTF concluded that current evidence is insufficient to recommend for or against routine screening (an “I” statement); this is not a recommendation against screening, and many clinicians still screen men aged 70 and older or younger men with significant risk factors, using clinical judgment.
The FRAX tool (developed at the University of Sheffield) estimates the 10-year probability of a major osteoporotic fracture and of a hip fracture based on clinical risk factors, with or without BMD data. In the United States, treatment is generally considered when the 10-year probability of a major osteoporotic fracture exceeds about 20 percent or the 10-year probability of a hip fracture exceeds about 3 percent — but these thresholds guide, rather than dictate, an individualized decision made with your clinician.
Beyond DXA, additional evaluation may include blood tests to assess calcium, vitamin D, thyroid function, parathyroid hormone, kidney function, and, in some cases, markers of bone turnover, to look for secondary causes. Vertebral fracture assessment (VFA), a low-dose lateral spine image obtained during DXA scanning, can detect vertebral compression fractures that were never clinically recognized. Such silent fractures, if present, can change the treatment decision regardless of the T-score.
Prevention: Building and Preserving Bone
Prevention begins in childhood and adolescence, when maximizing peak bone mass through good nutrition and physical activity lays the foundation for lifelong skeletal health. According to NIAMS, the great majority of peak bone mass is acquired by the end of the teenage years.
Calcium is the primary mineral in bone, and adequate intake matters throughout life. General dietary targets from the National Academy of Medicine are about 1,000 mg daily for most adults, rising to 1,200 mg daily for women over 50 and for all adults over 70. Food sources — dairy products, fortified plant milks, leafy greens, canned fish with soft bones such as sardines, and tofu — are generally preferred over supplements. When supplements are needed, calcium carbonate (taken with food) and calcium citrate (which can be taken on an empty stomach) are common forms. These are general population targets, not a prescription; your clinician can advise on the right amount for you, since more is not always better.
Vitamin D is critical for calcium absorption. General guidance suggests about 600 IU daily for adults up to age 70 and 800 IU for those over 70, though some people — particularly those with limited sun exposure or documented deficiency — need more under a clinician’s guidance. Vitamin D deficiency is common. Testing and any higher-dose repletion should be directed by your clinician rather than self-prescribed, as very high doses carry their own risks.
Weight-bearing exercise (such as walking, jogging, dancing, and stair climbing) and resistance training (weightlifting, resistance bands) both help stimulate bone formation and slow bone loss. Balance and coordination exercises such as tai chi reduce fall risk — and because falls are the proximate cause of most fractures, fall prevention is as important as bone strengthening. Not smoking and limiting alcohol are additional evidence-based strategies.
Pharmacological Treatment
When prevention is not enough and osteoporosis is diagnosed — or when fracture risk is high — medication can substantially reduce the chance of future fractures. The Endocrine Society and other professional organizations recommend drug treatment for postmenopausal women and older men who have had a hip or vertebral fracture, who have a T-score of -2.5 or below at the hip or spine, or who have a T-score in the osteopenia range together with a FRAX-calculated fracture risk that meets treatment thresholds. Which medicine is appropriate, how it is dosed, how long it is used, and how treatments are sequenced are decisions your clinician makes and monitors. The overview below is for understanding, not self-treatment, and contains no dosing.
Antiresorptive Medications
Bisphosphonates are the most commonly prescribed first-line agents. Alendronate (Fosamax), risedronate (Actonel), and ibandronate (Boniva) are oral bisphosphonates, while zoledronic acid (Reclast) is given as an intravenous infusion. Bisphosphonates work by inhibiting osteoclast activity, slowing bone breakdown, and they meaningfully reduce spine and hip fracture risk. Because oral bisphosphonates can irritate the esophagus, they are taken according to specific administration instructions from the prescriber — on an empty stomach with a full glass of water, remaining upright afterward. Rare but recognized risks of long-term bisphosphonate (and denosumab) use include osteonecrosis of the jaw and atypical femur fractures; these are uncommon and are weighed against the well-documented benefit of preventing fractures.
Denosumab (Prolia) is a monoclonal antibody given as a subcutaneous injection on a schedule set by the prescriber. It blocks RANK ligand, a key driver of osteoclast formation, and does not require kidney-related dose adjustment, which historically made it attractive for some patients with reduced kidney function. Two important cautions apply. First, denosumab must not simply be stopped or delayed: discontinuation can trigger a rapid rebound in bone loss and an increased risk of multiple vertebral fractures, so a transition to another agent is required if it is stopped — never stop it on your own. Second, in 2024 the U.S. FDA added a boxed warning about the risk of severe, potentially life-threatening low blood calcium (hypocalcemia) in patients with advanced chronic kidney disease, particularly those on dialysis; such patients need careful monitoring or an alternative. Denosumab biosimilars have also become available in recent years, which may affect cost. All of this is managed by the prescribing clinician.
Anabolic (Bone-Building) Medications
Teriparatide (Forteo) and abaloparatide (Tymlos) are parathyroid-hormone-pathway agents that stimulate new bone formation rather than only slowing breakdown. They are given as daily subcutaneous injections for a limited period and are typically reserved for people with severe osteoporosis, multiple fractures, or those who continue to fracture or lose bone despite other therapy. Romosozumab (Evenity) is a sclerostin inhibitor with both bone-building and antiresorptive effects, given as monthly injections for a defined course. It produces large gains in bone density, but it carries a cardiovascular safety signal (a boxed warning) and is generally avoided in people who have recently had a heart attack or stroke or who are at high cardiovascular risk.
A key principle: after completing a course of an anabolic agent, patients transition to an antiresorptive medicine (typically a bisphosphonate or denosumab) to preserve the bone density gained — the gains are lost quickly if nothing follows. Understanding the cost landscape of these medications is relevant, since anabolic agents are considerably more expensive than bisphosphonates. Your clinician sequences and monitors all of this.
Fall Prevention
Since most fractures result from falls, a complete osteoporosis plan must include fall prevention. The CDC reports that about one in four Americans aged 65 and older falls each year, and falls are the leading cause of injury-related death in this age group.
Home safety modifications include removing tripping hazards (loose rugs, clutter, electrical cords), installing grab bars in bathrooms, improving lighting, and using non-slip mats. Regular vision checks matter, as impaired vision increases fall risk. A medication review is essential — sedatives, some blood-pressure medicines, and taking many medications at once are all associated with increased fall risk, and only your prescriber should adjust these. Footwear matters too: well-fitting, low-heeled shoes with non-slip soles are safer than slippers, socks alone, or high heels.
Exercise programs that include balance training have been shown to reduce fall rates. Tai chi, in particular, has good evidence for fall prevention among older adults. Physical therapy can help people with gait or balance problems develop a personalized plan.
Frequently Asked Questions
Can osteoporosis be reversed?
Medications can significantly increase bone density and reduce fracture risk, but they generally don’t fully restore bone to its peak-density state. Anabolic agents such as teriparatide, abaloparatide, and romosozumab produce the largest density gains — some patients improve enough to move from the osteoporosis range into osteopenia. Even bisphosphonates increase density modestly while substantially cutting fracture risk. “Reversal” may not be the exact word, but meaningful, clinically important improvement is achievable under a clinician’s care.
How often should I get a bone-density test?
Intervals are individualized. For women who begin screening at 65 with normal bone density, repeat testing is often not needed for many years. For those with osteopenia, the interval depends on the degree of bone loss — mild osteopenia may warrant retesting in several years, while more significant osteopenia may warrant retesting sooner. If you are being treated for osteoporosis, your clinician will typically repeat DXA periodically to monitor your response. Your own schedule should come from your clinician.
Do men get osteoporosis?
Yes. Roughly 2 million American men have osteoporosis, and a meaningful share of hip fractures occur in men. Men tend to develop osteoporosis later than women because they start with higher peak bone mass and don’t go through the abrupt hormonal change of menopause. However, age-related testosterone decline, long-term corticosteroid use, hypogonadism, and other secondary causes all contribute. Osteoporosis is underdiagnosed and undertreated in men, so men with risk factors should discuss screening with their clinician.
Are there side effects of osteoporosis medications?
All medications carry potential side effects. Oral bisphosphonates can cause gastrointestinal irritation, which correct administration minimizes. Rare but serious risks of long-term bisphosphonate and denosumab use include osteonecrosis of the jaw and atypical femur fractures; denosumab additionally carries a warning about severe low calcium in advanced kidney disease and must not be stopped without a transition plan. Anabolic agents have their own considerations, and romosozumab carries a cardiovascular warning. These risks are weighed against the well-documented benefit of preventing fractures, and your clinician will help you navigate the balance for your situation.
Is osteopenia the same as osteoporosis?
No. Osteopenia is an intermediate category between normal bone density and osteoporosis — a T-score between -1.0 and -2.5. It indicates lower-than-normal bone density but does not always require medication. Many people with osteopenia do well with lifestyle measures: adequate calcium and vitamin D, weight-bearing exercise, and fall prevention. However, if FRAX scoring shows high fracture risk, or there is a history of a fragility fracture, medication may be appropriate even with osteopenia — a decision for you and your clinician.
Protecting Your Bones: What to Do Now
If you’re a woman 65 or older, a postmenopausal woman younger than 65 with risk factors, or an older man or younger man with significant risk factors, talk with your clinician about a DXA scan if you haven’t had one. If you’ve been diagnosed with osteoporosis or osteopenia, work with your clinician on a comprehensive plan that addresses both bone strength and fall prevention. Don’t wait for a fracture to take action — the consequences of hip and vertebral fractures are too significant to leave to chance.
Regardless of your current bone density, the fundamentals apply at every age: get enough calcium and vitamin D (from food first, supplements as needed and as advised), do regular weight-bearing and resistance exercise, don’t smoke, limit alcohol, and make your home safer. If you take corticosteroids or other bone-depleting medications, discuss bone-protection strategies with your prescribing clinician.
Osteoporosis may be silent, but the fractures it causes are anything but. With current screening tools, effective clinician-directed medications, and evidence-based prevention, this is a condition where early intervention and consistent management can help preserve your mobility, independence, and quality of life for years to come.
Sources
- NIAMS / NIH — osteoporosis overview and bone health
- U.S. Preventive Services Task Force — osteoporosis screening recommendation (2025)
- Bone Health & Osteoporosis Foundation (formerly the National Osteoporosis Foundation) — patient guidance
- Mayo Clinic — osteoporosis symptoms and causes
- Endocrine Society — clinical practice guidelines on osteoporosis treatment
- CDC — older adult falls prevention